|
NL188581C
(nl)
*
|
1974-07-15 |
1992-08-03 |
Akzo Nv |
Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
|
|
ZA763131B
(en)
*
|
1975-05-27 |
1978-01-25 |
Syntex Inc |
Use of flunisolide to treat respiratory diseases
|
|
SE8008524L
(sv)
*
|
1980-12-04 |
1982-06-05 |
Draco Ab |
4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
|
|
IT1196142B
(it)
*
|
1984-06-11 |
1988-11-10 |
Sicor Spa |
Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
|
|
SE8604059D0
(sv)
*
|
1986-09-25 |
1986-09-25 |
Astra Pharma Prod |
A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
|
|
GR1001529B
(el)
*
|
1990-09-07 |
1994-03-31 |
Elmuquimica Farm Sl |
Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
|
|
SE9100341D0
(sv)
*
|
1991-02-04 |
1991-02-04 |
Astra Ab |
Novel steroids
|
|
DK0678097T3
(da)
*
|
1993-01-08 |
2000-02-07 |
Astra Ab |
Hidtil ukendte colon- eller ileumspecifikke steroidderivater
|
|
DE19635498A1
(de)
*
|
1996-09-03 |
1998-03-26 |
Byk Gulden Lomberg Chem Fab |
Verfahren zur Epimerenanreicherung
|
|
IT1291288B1
(it)
|
1997-04-30 |
1999-01-07 |
Farmabios Srl |
Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
|
|
US6266556B1
(en)
|
1998-04-27 |
2001-07-24 |
Beth Israel Deaconess Medical Center, Inc. |
Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
|
|
IL144900A
(en)
|
2001-08-14 |
2013-12-31 |
Neurim Pharma 1991 |
Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
|
|
WO2005021515A2
(en)
*
|
2003-08-29 |
2005-03-10 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-iv
|
|
US20070259874A1
(en)
*
|
2003-11-26 |
2007-11-08 |
Palle Venkata P |
Phosphodiesterase Inhibitors
|
|
US7750151B2
(en)
|
2004-04-09 |
2010-07-06 |
Merck Sharp & Dohme Corp. |
Inhibitors of Akt activity
|
|
ATE550019T1
(de)
|
2005-05-17 |
2012-04-15 |
Merck Sharp & Dohme |
Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
|
|
US7915286B2
(en)
|
2005-09-16 |
2011-03-29 |
Ranbaxy Laboratories Limited |
Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
|
|
CA2626628A1
(en)
*
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type iv inhibitors
|
|
WO2007045979A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
|
WO2008035315A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type-iv
|
|
WO2008035316A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
|
PT2099442E
(pt)
|
2006-12-26 |
2015-02-10 |
Pharmacyclics Inc |
Métodos de utilização de inibidores de histona desacetilase e monitorização de biomarcadores em terapia de combinação
|
|
US8071623B2
(en)
|
2007-01-10 |
2011-12-06 |
Instituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
|
|
EP1958947A1
(en)
|
2007-02-15 |
2008-08-20 |
Ranbaxy Laboratories Limited |
Inhibitors of phosphodiesterase type 4
|
|
EP2124943A1
(en)
*
|
2007-03-14 |
2009-12-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
|
|
CN103497185A
(zh)
|
2007-03-14 |
2014-01-08 |
兰贝克赛实验室有限公司 |
用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
|
|
CA2690191C
(en)
|
2007-06-27 |
2015-07-28 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
|
ITMI20080645A1
(it)
|
2008-04-11 |
2009-10-12 |
Ind Chimica Srl |
Procedimento per la preparazione di budesonide
|
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
|
GB0900484D0
(en)
|
2009-01-13 |
2009-02-11 |
Angeletti P Ist Richerche Bio |
Therapeutic agent
|
|
EP2413932A4
(en)
|
2009-04-01 |
2012-09-19 |
Merck Sharp & Dohme |
INHIBITORS OF AKT ACTIVITY
|
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
|
EA025191B1
(ru)
*
|
2009-09-11 |
2016-11-30 |
КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. |
Производные прегнана, конденсированные по положению 16,17 с n-замещенным изоксалидиновым кольцом, в качестве противовоспалительных агентов
|
|
GB0916608D0
(en)
|
2009-09-22 |
2009-11-04 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
WO2011046771A1
(en)
|
2009-10-14 |
2011-04-21 |
Schering Corporation |
SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
|
|
JP2013518909A
(ja)
|
2010-02-08 |
2013-05-23 |
キナゲン，インク． |
アロステリックキナーゼ阻害が関係する治療方法および組成物
|
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
|
EP3330377A1
(en)
|
2010-08-02 |
2018-06-06 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
|
|
KR102072631B1
(ko)
|
2010-08-17 |
2020-02-03 |
시르나 쎄러퓨틱스 인코퍼레이티드 |
짧은 간섭 핵산 （ｓｉＮＡ）을 사용한 Ｂ형 간염 바이러스 （ＨＢＶ） 유전자 발현의 ＲＮＡ 간섭 매개 억제
|
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
|
EP2613782B1
(en)
|
2010-09-01 |
2016-11-02 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
|
EP3327125B1
(en)
|
2010-10-29 |
2020-08-05 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
|
|
US9351965B2
(en)
|
2010-12-21 |
2016-05-31 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as ERK inhibitors
|
|
WO2012143874A1
(en)
|
2011-04-21 |
2012-10-26 |
Piramal Healthcare Limited |
A process for the preparation of morpholino sulfonyl indole derivatives
|
|
CN103917231B
(zh)
|
2011-09-13 |
2016-09-28 |
药品循环有限责任公司 |
组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
|
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
EP3919620A1
(en)
|
2012-05-02 |
2021-12-08 |
Sirna Therapeutics, Inc. |
Short interfering nucleic acid (sina) compositions
|
|
NZ704799A
(en)
|
2012-08-24 |
2018-06-29 |
Univ Texas |
Heterocyclic modulators of hif activity for treatment of disease
|
|
US9155747B2
(en)
*
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
|
WO2014052563A2
(en)
|
2012-09-28 |
2014-04-03 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
|
CA2892361A1
(en)
|
2012-11-28 |
2014-06-05 |
Merck Sharp & Dohme Corp. |
Use of a wee1 inhibitor for treating a cancer characterized by low pkmyt1 expression levels
|
|
JP6387013B2
(ja)
|
2012-12-20 |
2018-09-12 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
Ｈｄｍ２阻害薬としての置換されたイミダゾピリジン類
|
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
|
WO2015034925A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
|
WO2017222951A1
(en)
|
2016-06-23 |
2017-12-28 |
Merck Sharp & Dohme Corp. |
3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
|
|
WO2018071283A1
(en)
|
2016-10-12 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Kdm5 inhibitors
|
|
JP7330101B2
(ja)
|
2016-11-08 |
2023-08-21 |
レゲネロン ファーマシューティカルス，インコーポレーテッド |
ステロイド及びそのタンパク質コンジュゲート
|
|
KR20200007905A
(ko)
|
2017-05-18 |
2020-01-22 |
리제너론 파마슈티칼스 인코포레이티드 |
사이클로덱스트린 단백질 약물 접합체
|
|
IL274427B2
(en)
|
2017-11-07 |
2024-11-01 |
Regeneron Pharma |
Hydrophilic linkers for antibody drug conjugates
|
|
WO2019094312A1
(en)
|
2017-11-08 |
2019-05-16 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|
|
SG11202006510XA
(en)
|
2018-01-08 |
2020-08-28 |
Regeneron Pharma |
Steroids and antibody-conjugates thereof
|
|
US11377502B2
(en)
|
2018-05-09 |
2022-07-05 |
Regeneron Pharmaceuticals, Inc. |
Anti-MSR1 antibodies and methods of use thereof
|
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
|
MA53287A
(fr)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme |
Inhibiteurs de prmt5
|
|
EP3833668B1
(en)
|
2018-08-07 |
2025-03-19 |
Merck Sharp & Dohme LLC |
Prmt5 inhibitors
|
|
JP7589247B2
(ja)
|
2019-12-17 |
2024-11-25 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｐｒｍｔ５阻害剤
|
|
TW202423928A
(zh)
|
2022-09-02 |
2024-06-16 |
美商默沙東有限責任公司 |
源自依克沙替康(exatecan)之拓樸異構酶-1抑制劑醫藥組合物及其用途
|
|
AU2023366166A1
(en)
|
2022-10-25 |
2025-05-01 |
Merck Sharp & Dohme Llc |
Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
|
|
AU2023397331A1
(en)
|
2022-12-14 |
2025-06-26 |
Merck Sharp & Dohme Llc |
Auristatin linker-payloads, pharmaceutical compositions, and uses thereof
|